Rapid quantitative analysis of 8-iso-prostaglandin-F2α using liquid chromatography-tandem mass spectrometry and comparison with an enzyme immunoassay method

Analytical Biochemistry

Volumn 404, Issue 2, 2010, Pages 211-216

  Dahl, Jeffrey H ^a   van Breemen, Richard B ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Biomarker; Enzyme immunoassay; Mass spectrometry; Quantitative analysis

Indexed keywords

BIOMARKERS; CHEMICAL ANALYSIS; ENZYMES; HIGH PRESSURE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; ISOMERS; LIPIDS; MASS SPECTROMETRY;

AFFINITY PURIFICATION; CHROMATOGRAPHIC SEPARATIONS; ENZYME IMMUNOASSAY; FRAGMENTATION PATTERNS; LIMITS OF DETECTION AND QUANTITATION; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ASSAYS;

DRUG PRODUCTS;

8 ISOPROSTAGLANDIN F2 ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; BIOLOGICAL MARKER; PROSTAGLANDIN F2 ALPHA;

ACCURACY; ARTICLE; ENZYME IMMUNOASSAY; HUMAN; INTERMETHOD COMPARISON; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; URINALYSIS; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES; URINE;

BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DINOPROST; HUMANS; IMMUNOENZYME TECHNIQUES; LIPID PEROXIDATION; TANDEM MASS SPECTROMETRY;

EID: 77954457844     PISSN: 00032697     EISSN: 10960309     Source Type: Journal    
DOI: 10.1016/j.ab.2010.05.023     Document Type: Article

References (21)

1. Laight D., Desai K., Gopaul N., Änggård E., Carrier M. F2 isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: Effects of vitamin E. Eur. J. Pharmacol. 1999, 377:89-92.
2. Greco A., Minghetti L., Levi G. Isoprostanes, novel markers of oxidative injury, help understanding the pathogenesis of neurodegenerative diseases. Neurochem. Res. 2000, 25:1357-1364.
3. Devaraj S., Hirany S., Burk R., Jialal I. Divergence between LDL oxidative susceptibility and urinary F2-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin. Chem. 2001, 47:1974-1979.
4. Pratico D., Lee V.M.-Y., Trojanowski J., Rokach J., Fitzgerald G. Increased F2-isoprostanes in Alzheimer's disease: Evidence for enhanced lipid peroxidation in vivo. FASEB J. 1998, 12:1777-1783.
5. Basu S., Helmersson J. Factors regulating isoprostane formation in vivo. Antioxid. Redox Signal. 2005, 7:221-235.
6. Chehne F., Oguogho A., Lupattelli G., Palumbo B., Sinzinger H. Effect of giving up cigarette smoking and restarting in patients with clinically manifested atherosclerosis Prostaglandins Leukot. Essent. Fatty Acids 2002, 67:333-339.
7. Wang Z., Ciabattoni G., Creminon C., Lawson J., Fitzgerald G., Patrono C., Maclouf J. Immunological characterization of urinary 8-epiprostaglandin F2α excretion in man. J. Pharmacol. Exp. Ther. 1995, 275:94-100.
8. Ohashi N., Yoshikawa M. Rapid and sensitive quantification of 8-isoprostaglandin F2α in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. B 2000, 746:17-24.
9. Roberts L., Morrow J. Measurement of F2-isoprostanes as an index of oxidative stress in vivo. Free Radic. Biol. Med. 2000, 28:505-513.
10. Taylor A., Bruno R., Frei B., Traber M. Benefits of prolonged gradient separation for high-performance liquid chromatography-tandem mass spectrometry quantitation of plasma total 15-series F2-isoprostanes. Anal. Biochem. 2006, 350:41-51.
11. Morrow J., Harris T., Jackson Roberts L. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. Anal. Biochem. 1990, 184:1-10.
12. Roberts L., Moore K., Zackert W., Oates J., Morrow J. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2α in humans. J. Biol. Chem. 1996, 271:20617-20620.
13. Taylor A., Bruno R., Traber M. Women and smokers have elevated urinary F2-isoprostane metabolites: A novel extraction and LC-MS methodology. Lipids 2008, 43:925-936.
14. Morrow J., Roberts L. Mass spectrometry of prostanoids: F2 isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol. 1994, 233:163-174.
15. Li H., Lawson J., Reilly M., Adiyaman M., Hwang S., Rokach J., FitzGerald G. Quantitative high performance liquid chromatography/tandem mass spectrometric analysis of the four classes of F2 isoprostanes in human urine. Proc. Natl. Acad. Sci. USA 1999, 96:13381-13386.
16. Bastani N., Gundersen T., Blomhoff R. Determination of 8-epi-PGF2α concentrations as a biomarker of oxidative stress using triple-stage liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2009, 23:2885-2890.
17. Liang Y., Wei P., Duke R., Reaven P., Harman S., Cutler R., Heward C. Quantification of 8-iso-prostaglandin-F2α and 2, 3-dinor-8-iso-prostaglandin-F2α in human urine using liquid chromatography-tandem mass spectrometry. Free Radic. Biol. Med. 2003, 34:409-418.
18. Guidance for Industry Bioanalytical Method Validation [technical report], FDA 2001, U.S. Food and Drug Administration, Washington, DC.
19. Harris D. Quantitative Chemical Analysis 2003, Macmillan, New York.
20. Morrow J., Hill K., Burk R., Nammour T., Badr K., Roberts L. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase Free radical-catalyzed mechanism. Proc. Natl. Acad. Sci. USA 1990, 87:9383-9387.
21. Davies S., Zackert W., Luo Y., Cunningham C., Frisard M., Roberts L. Quantification of dinor, dihydro metabolites of F2-isoprostanes in urine by liquid chromatography/tandem mass spectrometry. Anal. Biochem. 2006, 348:185-191.